ArticleEClinicalMedicine2025

Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial.

Tao Ge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.